Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) exceeded analyst estimates by 4.9%. Looking ahead, revenue is forecast to grow 28% p.a. on average during the next 3 years, compared ...
Maxim Group analyst Anthony Vendetti has reiterated their bullish stance on ECOR stock, giving a Buy rating yesterday. Anthony Vendetti has ...
Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Greetings, and welcome to the electroCore Third Quarter 2024 ...
Electrocore (ECOR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula ...
Researchers at New York University have devised a mathematical approach to predict the structures of crystals—a critical step in developing many medicines and electronic devices—in a matter of ...
Daniel Baker, M.D., will join Cue Biopharma's executive team as interim chief development officer (CDO), effective Monday, ...
Despite achieving its eighth consecutive record revenue quarter, electroCore Inc (ECOR) faces hurdles with net losses and ...
Zacks.com on MSN2d
ElectroCore, Inc. (ECOR) Reports Q3 Loss, Tops Revenue EstimatesElectroCore, Inc. (ECOR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.68 per share a year ago. These figures ...
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax ...
For the quarter ended September 30, 2024, electroCore reported net sales of $6.6 million compared to $4.5 million during the same period of 2023, which represents an approximate 45% increase over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback